Somavert market seen growing steadily through 2030
The Somavert market is projected to rise from $0.27 million in 2025 to $0.34 million by 2030, driven by more acromegaly diagnoses, wider use of specialty therapies and growing rare-disease awareness. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.
Why it matters: - Somavert is used to treat acromegaly, a rare endocrine disorder that can cause serious long-term complications if growth hormone levels stay elevated. - The market’s projected growth signals continued demand for targeted therapies in rare diseases, where surgical options and older treatments do not fully meet patient needs. - Expanding diagnosis and specialty care could push more patients into treatment pathways that include pegvisomant-based therapy.
What happened: - The Business Research Company projected the Somavert market will grow from $0.27 million in 2025 to $0.28 million in 2026, a 4.8% CAGR. - The report forecasts the market will reach $0.34 million by 2030, at a 4.5% CAGR. - The report was released as part of The Business Research Company’s Somavert Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - North America held the largest share of the Somavert market in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the next several years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report. - View the full market report.
The details: - Somavert contains pegvisomant, a growth hormone receptor antagonist. - The drug is used to control elevated growth hormone levels in patients with acromegaly who have not responded sufficiently to other treatments. - Somavert helps reduce insulin-like growth factor-1, which supports symptom control and lowers the risk of complications. - The report links market growth to limited effectiveness of surgery, reliance on somatostatin analogs, better endocrine diagnostics, more specialist care centers and unmet need in refractory acromegaly. - The report also cites rising awareness of rare endocrine diseases, broader use of long-acting injectable therapies, better adherence programs, growth in specialty clinic services and higher healthcare spending on rare conditions. - The report highlights a trend toward more acromegaly diagnoses, greater adoption of growth hormone receptor antagonists and longer-term disease management. - The report points to expanded treatment for resistant cases and continued growth in specialized endocrinology care. - The report identifies rising acromegaly prevalence as a major demand driver. - Research from the Barrow Neurological Institute in May 2024 reported roughly 10 new acromegaly cases per million people annually in the United States. - The report also ties growth to broader increases in chronic and rare diseases. - Allergy UK reported in April 2024 that more than 21 million people in the UK suffer from allergies, the most commonly reported chronic condition. - The Personalized Medicine Coalition said the USFDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - The Center for Drug Evaluation and Research reported in January 2024 that it approved 55 novel drugs in 2023, including 36% first-in-class therapies, compared with 37 novel drug approvals in 2022.
Between the lines: - The market remains small in absolute dollar terms, but the forecast suggests a durable niche driven by chronic management rather than one-time treatment. - Growth appears tied less to blockbuster volume and more to better diagnosis, specialty access and the long tail of patients who need sustained therapy. - The report’s emphasis on rare disease approvals suggests a broader industry shift toward targeted medicines for smaller patient populations.
What's next: - More acromegaly diagnoses could gradually expand the treatable patient pool. - Wider adoption of long-acting injectable therapies and adherence support may improve persistence on treatment. - Specialty endocrinology clinics and rare-disease spending are likely to remain key supports for market growth through 2030. - The Asia-Pacific region could narrow the gap with North America if diagnosis and specialty care access continue to improve. - The report’s updated tools, including TAM analysis, forecasting dashboards and trend graphics, indicate continued monitoring of this niche market.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
UK Post Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.